News & Media

The Ketamine Conference: A Molecular Masterclass

Molecular Masterclass Ketamine Conference presented by Jeffrey Becker, M.D.

The Ketamine Conference: A Molecular Masterclass is set to take place today, featuring a host of experts in the delivery of ketamine therapy for resistant conditions such as PTSD, depression, and anxiety. Presented by Bexson Biomedical, The Conscious Fund, and Microdose, it will bring together leaders in the field of ketamine science and delivery, and will translate the […]

0 comments

The Next Covid Crisis Could Be a Wave of Suicides

Isolation and anxiety are a recipe for substance abuse and mental illness. A new study predicts 75,000 “deaths of despair.” By Cynthia Koons, Riley Griffin, and Emma Court May 7, 2020, 9:14 PM PDT The isolation, grief and economic hardship related to Covid-19 are creating a mental health crisis in the U.S. that researchers warn could make the already-rising suicide […]

0 comments

Ketamine’s promise as an antidepressant is being undermined by its lack of profit

Esketamine, the first new method to treat depression in 25 years, isgaining credibility. Last year, Janssen Pharmaceutical’s ketaminebaseddrug was approved by the US Food and Drug Administration(FDA) to treat patients with treatment-resistant depression. And onAug. 3, the FDA followed up with a second approval, allowing doctorsto prescribe the tranquilizing drug to patients experiencing suicidalideation. But […]

0 comments

Suicide Mortality and Coronavirus Disease 2019: A Perfect Storm?

Mark A. Reger, PhD1,2;  Ian H. Stanley, MS1,3;  Thomas E. Joiner, PhD3 Author Affiliations: Article Information JAMA Psychiatry. Published online April 10, 2020. doi:10.1001/jamapsychiatry.2020.1060 Suicide rates have been rising in the US over the last 2 decades. The latest data available (2018) show the highest age-adjusted suicide rate in the US since 1941.1 It is within this context that coronavirus disease 2019 (COVID-19) […]

0 comments

Houston based depression psychiatrist, Dr. Sandhya Prashad, M.D., tells how this new drug might save lives and cost less than expected

FDA approves Spravato, a version of ketamine backed by Johnson & Johnson that sees rapid results in patients battling treatment resistant depression and suicide. HOUSTON, March 5, 2019 /PRNewswire/ — “New FDA approved depression treatment, esketamine, is the biggest advancement in depression treatment in thirty years” – says Houston based Psychiatrist, Dr. Sandhya Prashad. This approval allows ketamine treatments to be […]

0 comments

Side effects mild, brief with single antidepressant dose of intravenous ketamine

Safety data analyzed from five NIH inpatient clinical trials. National Institutes of Health researchers found that a single, low-dose ketamine infusion was relatively free of side effects for patients with treatment-resistant depression. Elia Acevedo-Diaz, M.D., Carlos Zarate, M.D., and colleagues at the NIH’s National Institute of Mental Health (NIMH) report their findings in the Journal of Affective […]

0 comments

CT Psychiatrist Shows Titrated IV Ketamine Can STOP Suicidality

Data Published from a Real World Psychiatry Practice Shows How Ketamine Infusions Can Avert ER Trips and Hospitalizations SOUTH WINDSOR, Conn., Oct. 8, 2019 /PRNewswire/ — Lori Calabrese, M.D., Innovative Psychiatry (https://loricalabresemd.com). Local psychiatrist publishes data demonstrating that the use of a series of IV ketamine infusions, with dose adjustments, can stop suicidal thoughts and avert ER trips […]

0 comments

CT doctors using new nasal spray to treat severely depressed patients

By Peggy McCarthy, Conn. Health I-Team Writer Published 11:51 am EDT, Tuesday, August 13, 2019 Some Connecticut hospitals and doctors and a clinic are starting to treat severely depressed patients with a new nasal spray called Spravato, touted as the most significant federally approved depression medication since Prozac was approved in 1987. Spravato, which received Food and Drug Administration […]

0 comments

Nasal spray Spravato, offering fresh hope for severely depressed patients, arrives in Connecticut

Spravato, which received Food and Drug Administration (FDA) approval in March, has raised hopes for preventing suicides and relieving depression after other treatments have failed. But there are concerns about possible side effects, including drug abuse, elevated blood pressure and heart rate, sedation, and hypersensitivity to surroundings. The nasal spray is prescribed for treatment-resistant depression after at […]

0 comments